Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT-77 in Erythropoietic Protoporphyria
NCT06971900Phase 2Completed
- Sponsor
- Portal Therapeutics
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of port-77 in erythropoietic protoporphyria (EPP), sponsored by Portal Therapeutics. Started Apr 2025; status: completed.
02
Drugs
port-77
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT06971900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971900.